Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 16/20 | 0.67 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.46 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | STK17A | Q9UEE5 | 4/20 | 0.44 |
| ▸ | MARK3 | P27448 | 3/20 | 0.44 |
| ▸ | MARK4 | Q96L34 | 3/20 | 0.44 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.43 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.43 |
| ▸ | ULK1 | O75385 | 1/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.43 |
| ▸ | SIK1 | P57059 | 1/20 | 0.43 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.43 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.43 |
| ▸ | MELK | Q14680 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.43 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.43 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.43 |
| ▸ | MARK1 | Q9P0L2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1284579 | 0.91 | TBK1 (0.59) | TBK1MARK3ULK1IKBKEULK2 | |
| SCHEMBL15163536 | 0.90 | TBK1 (0.53) | TBK1PRKCQPDPK1CCR3STK17A | |
| SCHEMBL1285556 | 0.84 | TBK1 (0.72) | TBK1PDPK1STK17AMARK3MARK4 | |
| SCHEMBL1284924 | 0.83 | TBK1 (0.68) | TBK1PDPK1STK17AMARK3MARK4 | |
| SCHEMBL1284746 | 0.82 | TBK1 (0.72) | TBK1PDPK1STK17AMARK3MARK4 | |
| SCHEMBL1285068 | 0.82 | TBK1 (0.69) | TBK1PDPK1STK17AMARK3MARK4 | |
| SCHEMBL3714758 | 0.82 | PRKCQ (0.47) | TBK1PRKCQPDPK1STK17AMARK3 | |
| SCHEMBL3714755 | 0.81 | IRAK4 (0.44) | TBK1PRKCQPDPK1STK17AMARK3 | |
| SCHEMBL1285492 | 0.81 | TBK1 (0.70) | TBK1PDPK1STK17AMARK3MARK4 | |
| SCHEMBL1284573 | 0.81 | TBK1 (0.78) | TBK1PDPK1STK17AMARK3MARK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | claimed |
| EP-2403853-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | Medical Research Council Technology (GB) | 2012-01-11 | — | — | EP | claimed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
| EP-2403853-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | Medical Research Council Technology (GB) | 2012-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MARK3, MAPK8, CDK8 | TBK1 17/4885PRKCQ 203/4885PDPK1 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.